A Double Blind,Placebo Controlled,Parallel Group,Multicentre,Randomised,Phase Iii Survival Study Comparing ZD1839 (IRESSA™)(250mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced NSCLC Who Have Received One Or Two Prior Chemotherapy Regimens And Are Refractory Or Intolerant To Their Most Recent Regimen
A Double Blind,Placebo Controlled,Parallel Group,Multicentre,Randomised,Phase Iii Survival Study Comparing ZD1839 (IRESSA™)(250mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced NSCLC Who Have Received One Or Two Prior Chemotherapy Regimens And Are Refractory Or Intolerant To Their Most Recent Regimen
This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.
Inclusion Criteria:
· Life expectancy of at least 8 weeks.
Exclusion Criteria:
Capital Federal, Buenos Aires, Argentina
Monoton, New Brunswick, Canada
Saint Catherines, Ontario, Canada
Ste-Foy, Quebec, Canada
Various Cities, Chile
Talinn, Estonia
Muchen, Bavaria, Germany
Grobhansdorf, Germany
Ujronafj, Hungary
Zalaegerszeg-Pozva, Hungary
Karnataka, India
Beaumont Road, Ireland
Elm Park, Ireland
Nordbyhagen, Norway
Various Cities, Peru
Kojice, Slovakia
Nitra-Zobor, Slovakia
Poprad - Kvetnica, Slovakia
Prejov, Slovakia
Various Cities, Ukraine
Essex, United Kingdom
Gwynedd, United Kingdom
Various Cities, Venezuela